NASDAQ:CFRX - ContraFect Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.33
  • Forecasted Upside: 154.84 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$3.27
▲ +0.17 (5.48%)

This chart shows the closing price for CFRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ContraFect Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CFRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CFRX

Analyst Price Target is $8.33
▲ +154.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ContraFect in the last 3 months. The average price target is $8.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 154.84% upside from the last price of $3.27.

This chart shows the closing price for CFRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in ContraFect. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/8/2022WBB SecuritiesUpgradeStrong-Buy$7.00High
2/16/2022SVB LeerinkLower Price TargetOutperform$14.00 ➝ $9.00High
11/16/2021MizuhoLower Price TargetBuy$10.00 ➝ $9.00High
9/9/2021SVB LeerinkInitiated CoverageOutperform$14.00High
7/1/2021Chardan CapitalReiterated RatingBuyMedium
3/31/2021MizuhoReiterated RatingBuy$12.00 ➝ $10.00High
3/31/2021WBB SecuritiesInitiated CoverageSpeculative Buy$6.50High
3/16/2021Chardan CapitalBoost Price TargetBuy$15.00 ➝ $17.50Low
8/26/2020Maxim GroupReiterated RatingBuy$22.00Medium
7/21/2020Maxim GroupReiterated RatingBuy$22.00High
6/9/2020MizuhoInitiated CoverageBuy$12.00High
6/8/2020Cantor FitzgeraldInitiated CoverageOverweight$15.00Medium
6/7/2020Chardan CapitalReiterated RatingBuyMedium
3/19/2020Maxim GroupReiterated RatingBuy$22.00High
2/24/2020Chardan CapitalReiterated RatingBuy$15.00Low
12/19/2019Maxim GroupReiterated RatingBuy$20.00Low
10/4/2019Maxim GroupReiterated RatingBuy$20.00Medium
6/11/2019Maxim GroupInitiated CoverageBuyHigh
5/15/2019Chardan CapitalReiterated RatingBuy$15.00High
7/10/2018LADENBURG THALM/SH SHInitiated CoverageBuyHigh
6/28/2018Janney Montgomery ScottInitiated CoverageBuyHigh
6/15/2018Chardan CapitalInitiated CoverageBuy$28.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/5/2022

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

ContraFect logo
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Read More

Today's Range

Now: $3.27
Low: $3.16
High: $3.27

50 Day Range

MA: $3.39
Low: $2.79
High: $4.45

52 Week Range

Now: $3.27
Low: $2.11
High: $4.54

Volume

853 shs

Average Volume

188,686 shs

Market Capitalization

$128.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of ContraFect?

The following sell-side analysts have issued research reports on ContraFect in the last twelve months: Mizuho, StockNews.com, SVB Leerink LLC, and WBB Securities.
View the latest analyst ratings for CFRX.

What is the current price target for ContraFect?

0 Wall Street analysts have set twelve-month price targets for ContraFect in the last year. Their average twelve-month price target is $8.33, suggesting a possible upside of 154.8%.
View the latest price targets for CFRX.

What is the current consensus analyst rating for ContraFect?

ContraFect currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CFRX will outperform the market and that investors should add to their positions of ContraFect.
View the latest ratings for CFRX.

How do I contact ContraFect's investor relations team?

ContraFect's physical mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company's listed phone number is (914) 207-2300 and its investor relations email address is [email protected] The official website for ContraFect is www.contrafect.com. Learn More about contacing ContraFect investor relations.